Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
-
- Andrea Gallamini
- Hematology Department, Ospedale Santa Croce, Cuneo;
-
- Francesco Zaja
- Hematology Department, Università di Udine, Udine;
-
- Caterina Patti
- Hematology Department, Ospedale Cervello, Palermo, Sicily;
-
- Atto Billio
- Hematology Department, Ospedale Regionale Generale, Bolzano;
-
- Maria Rosaria Specchia
- Hematology Department, Ospedale Santa Giuseppe Moscati, Taranto;
-
- Alessandra Tucci
- Hematology Department, Ospedale Spedali Civili, Brescia;
-
- Alessandro Levis
- Hematology Department, Ospedale Santa Antonio e Biagio, Alessandria;
-
- Annunziata Manna
- Onco-Hematology Department, Ospedale Azienda Sanitaria Locale 5, La Spezia;
-
- Vicenzo Secondo
- Internal Medicine Department, Ospedale Galliera, Genova;
-
- Luigi Rigacci
- Hematology Department, Università di Firenze, Firenze;
-
- Antonello Pinto
- Onco-Hematology Department, Ospedale Pascale, Napoli;
-
- Emilio Iannitto
- Hematology Department, Università di Palermo, Palermo, Sicily;
-
- Valerio Zoli
- Hematology Department, Ospedale Santa Camillo Forlanini, Roma;
-
- Pierfederico Torchio
- Medical Statistics Department, Università di Torino, Torino;
-
- Stefano Pileri
- Hemolymphopathology Department, Università di Bologna, Bologna;
-
- Corrado Tarella
- Hematology Department, Università di Torino, Torino, Italy
抄録
<jats:p>To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day −1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follow-up of 16 months (range, 5-42 months), 14 patients were alive, 9 had died from progressive disease, and 1 had died from pneumonia at day +198 while in CR. So far, 13 are disease-free, with an overall median duration of response of 11 months. The most frequent side effects were grade 4 neutropenia and cytomegalovirus (CMV) reactivation. Major infections were Jacob-Creutzfeldt (J-C) virus reactivation, pulmonary invasive aspergillosis, Staphylococcus sepsis, and pneumonia. This study shows that CHOP-C: (1) is a feasible chemoimmunotherapy regimen; (2) is effective in PTCL with a high rate of CR achievement; and (3) is associated with mostly manageable infectious complications. This clinical trial was registered with the Osservatorio Nazionale sulla Sperimentazione cinica as ID no. 141202.</jats:p>
収録刊行物
-
- Blood
-
Blood 110 (7), 2316-2323, 2007-10-01
American Society of Hematology
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1362262945840209536
-
- NII論文ID
- 30029633159
-
- ISSN
- 15280020
- 00064971
- http://id.crossref.org/issn/00064971
-
- データソース種別
-
- Crossref
- CiNii Articles